First, decorin confers direct anti-myeloma effects by binding to several receptors on the MCs, such as Met, EGFR, and IGF-IR, which consequently degrades the receptors and downregulates downstream signaling, thereby inhibiting cell growth [11, 24]. Here, DCN is linked to plasma cell myeloma.